CF PharmTech Inc
02652
Company Profile
Business description
CF PharmTech Inc is focused on the R&D, manufacturing and commercialization of inhalation technologies and inhalation drugs, with a focus on treating respiratory diseases. It has developed a product portfolio with a broad coverage of patients, medical specialties, and therapeutic areas. Its products strategically benchmark global blockbuster drugs, covering four of the top ten inhalation drugs. Its first-approved product CF017, a budesonide suspension for inhalation targeting bronchial asthma, marked its first approved product.
Contact
No. 16, Hucundang Road
Xiangcheng Economic Development District
Jiangsu
Suzhou
CHNT: +86 51286867555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
164
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,243.94 | 37.87 | 0.46% |
| DAX 40 | 24,277.59 | 18.79 | 0.08% |
| Dow JONES (US) | 46,737.93 | 31.35 | 0.07% |
| FTSE 100 | 9,429.81 | 26.24 | 0.28% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,961.94 | 28.61 | -0.12% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,734.85 | 0.28 | -0.00% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |